Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H26N2S.ClH |
| Molecular Weight | 338.938 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN1C2=C(C=CC=C2)C3=C1C(C)(CCN(C)C)SCC3
InChI
InChIKey=FJJSKKBQSGDHQK-UHFFFAOYSA-N
InChI=1S/C18H26N2S.ClH/c1-5-20-16-9-7-6-8-14(16)15-10-13-21-18(2,17(15)20)11-12-19(3)4;/h6-9H,5,10-13H2,1-4H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H26N2S |
| Molecular Weight | 302.477 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Tandamine was developed as a selective serotonin reuptake inhibitor for the treatment of depression. Tandamine participated in clinical trials in hospitalized depressed patients, where it showed that the well-tolerated drug could be of some benefit for retarded depressions. In addition, was found in human volunteers, that tandamine possessed significant anticholinergic activity, to reduce appetite and to produce sedation. However, this drug has never been marketed.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of acute and chronic treatment of tandamine, a new heterocyclic antidepressant, on biogenic amine metabolism and related activities. | 1979-09 |
|
| Effects of tandamine and pirandamine, selective blockers of biogenic amine uptake mechanisms, on gastric acid secretion and ulcer formation in the rat. | 1977-04-15 |
|
| Clinical pharmacological studies of tandamine, a potential antidepressive drug. | 1977-03-23 |
|
| The effects of tandamine, a new potential antidepressant agent, on biogenic amine uptake mechanisms and related activities. | 1976-05-15 |
|
| Effects of tandamine and pirandamine, new potential antidepressants, on the brain uptake of norepinephrine and 5-hydroxytryptamine and related activities. | 1976-05-05 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/334686
was administered in doses from 75 to 200 mg to a group of 20 hospitalized depressed patients.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:41 GMT 2025
by
admin
on
Mon Mar 31 17:50:41 GMT 2025
|
| Record UNII |
7516K9UGUG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65474
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110652
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
C152507
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
58167-78-5
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
300000055275
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
42821-35-2
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
7516K9UGUG
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY | |||
|
305532
Created by
admin on Mon Mar 31 17:50:41 GMT 2025 , Edited by admin on Mon Mar 31 17:50:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |